The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
NLRP3 inflammasome activation drives tau pathology
Open accessAbstract
Alzheimer’s disease is characterized by the accumulation of amyloid-beta in plaques, aggregation of hyperphosphorylated tau in neurofibrillary tangles and neuroinflammation, together resulting in neurodegeneration and cognitive decline1. The NLRP3 inflammasome assembles inside of microglia on activation, leading to increased cleavage and activity of caspase-1 and downstream interleukin-1β release2. Although the NLRP3 inflammasome has been shown to be essential for the development and progression of amyloid-beta pathology in mice3, the precise effect on tau pathology remains unknown. Here we show that loss of NLRP3 inflammasome function reduced tau hyperphosphorylation and aggregation by regulating tau kinases and phosphatases. Tau activated the NLRP3 inflammasome and intracerebral injection of fibrillar amyloid-beta-containing brain homogenates induced tau pathology in an NLRP3-dependent manner. These data identify an important role of microglia and NLRP3 inflammasome activation in the pathogenesis of tauopathies and support the amyloid-cascade hypothesis in Alzheimer’s disease, demonstrating that neurofibrillary tangles develop downstream of amyloid-beta-induced microglial activation. The authors show that NLRP3 inflammasome is activated in microglia of patients with fronto-temporal dementia and in a mouse model of tau pathology, and that the loss of NLRP3 inflammasome function decreases tau pathology and improves cognition in mice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The NLRP3-ASC inflammasome mechanisms contributing to increased beta-amyloids and tau are thought to be a combination of kinases and phosphatases involved in tau phosphorylation [96] through the production of IL-1 beta.”
From The Role of Cortisol in Chronic Stress, Neurodegenerative Diseases, and Psychological Disorders (2023) · cites this paper as [96]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The activation of hippocampal NLRP3 inflammasome-mediated pyroptosis is associated with neuronal damage, cognitive decline, and neuronal death (Hanslik & Ulland, 2020; Heneka et al., 2013; Ising et al., 2019; Venegas et al., 2017).”
From Picroside II Alleviates the Progression of Alzheimer’s Disease via the NLRP3/Caspase-1/GSDMD Pathway (2025) · cites this paper as Ising et al., 2019
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“On the other hand, treatment of mouse primary hippocampal neurons with conditioned media from wild-type, but not Nlrp3−/− and Asc−/−, microglia primed with LPS resulted in elevated total and phosphorylated tau levels, suggesting that NLRP3 inflammasome activation in microglia can induce tau pathology in neurons.”
From Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease (2023) · cites this paper as [81]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Additionally, several cytokines, including IL-1β and IL-6, can directly induce tau phosphorylation in vitro, thus potentially contributing to the development of tau pathology.54”
From Amelioration of Tau and ApoE4-linked glial lipid accumulation and neurodegeneration with an LXR agonist (2024) · cites this paper as [56]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Research by Ising et al. suggests that tau proteins can activate the NLRP3 inflammasome, which then promotes excessive tau phosphorylation and aggregation by affecting specific tau kinases and phosphatases.252”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [252]
The cited source says what the claim attributes to it.
In the citing paper
“In turn, the NLRP3 inflammasome is essential for the development and progression of Aβ pathology in mice29 and may drive tau pathology through Aβ-induced microglial activation30.”
From New insights into the genetic etiology of Alzheimer’s disease and related dementias (2022) · cites this paper as [30]
The cited source says what the claim attributes to it.
In the citing paper
“On the other hand, microglia could also drive tau spreading and toxicity by promoting neuroinflammation, such as activating NACHT-, LRR- and pyrin (PYD)-domain-containing protein 3 (NLRP3) inflammasome155 or inducing NF-kB signaling.”
From Microglia in neurodegenerative diseases: mechanism and potential therapeutic targets (2023) · cites this paper as [155]
The cited source says what the claim attributes to it.
In the citing paper
“Tau oligomers and monomers can also activate NLRP3 inflammasomes, further perpetuating microglial activation [162] and potential progression of tau pathology.”
From Microglia and monocytes in inflammatory CNS disease: integrating phenotype and function (2022) · cites this paper as [162]
The cited source says what the claim attributes to it.
In the citing paper
“Treatment of wild-type primary microglia with recombinant wild-type tau and recombinant tau with a P301S mutation increased IL-1β secretion, an effect that was attenuated in Nlrp3−/− and Asc−/− microglia, suggesting that tau induces IL-1β secretion in a NLRP3-dependent manner [81].”
From Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease (2023) · cites this paper as [81]
The cited source says what the claim attributes to it.
In the citing paper
“Inhibiting or downregulating the NLRP3 inflammasome ameliorates AD neuropathology in animal models, which opens up a therapeutic avenue for modulators of NLRP3 activation in AD.”
From Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease (2023) · cites this paper as [81]
The cited source says what the claim attributes to it.
In the citing paper
“On the other hand, treatment of mouse primary hippocampal neurons with conditioned media from wild-type, but not Nlrp3−/− and Asc−/−, microglia primed with LPS resulted in elevated total and phosphorylated tau levels, suggesting that NLRP3 inflammasome activation in microglia can induce tau pathology in neurons.”
From Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease (2023) · cites this paper as [81]
The cited source says what the claim attributes to it.
In the citing paper
“Treatment of wild-type primary microglia with recombinant wild-type tau and recombinant tau with a P301S mutation increased IL-1β secretion, an effect that was attenuated in Nlrp3−/− and Asc−/− microglia, suggesting that tau induces IL-1β secretion in a NLRP3-dependent manner [81].”
From Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease (2023) · cites this paper as [81]
The cited source says what the claim attributes to it.
In the citing paper
“The NLRP3 inflammasome has a bidirectional relationship with AD-related tau pathology as well.”
From Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease (2023) · cites this paper as [81]
The cited source says what the claim attributes to it.
In the citing paper
“Evidence suggests that while some forms of tau can activate the NLRP3 inflammasome, inflammasome activation can exacerbate tau pathology by promoting elevated phosphorylation of tau [81, 82].”
From Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease (2023) · cites this paper as [81]
The cited source says what the claim attributes to it.
In the citing paper
“Moreover, treatment with brain homogenates from APP/PS1 mice induced tau hyperphosphorylation in a mouse model of tau aggregation pathology (Tau22) but not in Tau22/Nlrp3−/− and Tau22/Asc−/− mice, indicating the NLRP3 inflammasome as a mediator of Aβ-induced tau pathology [81].”
From Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease (2023) · cites this paper as [81]
The cited source says what the claim attributes to it.
In the citing paper
“Moreover, treatment with brain homogenates from APP/PS1 mice induced tau hyperphosphorylation in a mouse model of tau aggregation pathology (Tau22) but not in Tau22/Nlrp3−/− and Tau22/Asc−/− mice, indicating the NLRP3 inflammasome as a mediator of Aβ-induced tau pathology [81].”
From Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease (2023) · cites this paper as [81]
The cited source says what the claim attributes to it.
In the citing paper
“Evidence suggests that while some forms of tau can activate the NLRP3 inflammasome, inflammasome activation can exacerbate tau pathology by promoting elevated phosphorylation of tau [81, 82].”
From Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease (2023) · cites this paper as [81]
The cited source says what the claim attributes to it.
In the citing paper
“In Tau22 mice, ablation of Nlrp3 or Asc reduced levels of hyperphosphorylated tau and tau aggregates and rescued tau-induced spatial memory deficits [81].”
From Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease (2023) · cites this paper as [81]
In the citing paper
“Studies have demonstrated important roles of the NLRP3 inflammasome in aging and age-related diseases, such as atherosclerosis metabolic syndrome, type 2 diabetes, and Alzheimer’s disease (81–83).”
From Connecting aging biology and inflammation in the omics era (2022) · cites this paper as [83]
In the citing paper
“For example, in AD and frontotemporal dementia, neuroinflammation and microglia activation potentiate the spreading of pathological tau neurofibrillary tangles (83, 175).”
From Connecting aging biology and inflammation in the omics era (2022) · cites this paper as [83]
In the citing paper
“In AD, this relationship may be mediated by NLRP3 inflammasome activation in microglia, a process that activates tau kinases (e.g., GSK-3β and CaMKII-α) and results in tau hyperphosphorylation (83).”
From Connecting aging biology and inflammation in the omics era (2022) · cites this paper as [83]
In the citing paper
“The knockout of ASC or NLRP3 ameliorates AD‐like brain pathology in animal models. 68”
From Senescence, brain inflammation, and oligomeric tau drive cognitive decline in Alzheimer's disease: Evidence from clinical and preclinical studies (2024) · cites this paper as [68]
In the citing paper
“The activation of the NLRP3 inflammasome drives tau pathology. 68”
From Senescence, brain inflammation, and oligomeric tau drive cognitive decline in Alzheimer's disease: Evidence from clinical and preclinical studies (2024) · cites this paper as [68]
In the citing paper
“Inflammaging can drive tau pathology and neurodegeneration in AD by impairing the clearance of Aβ peptides, altering BBB integrity, and affecting the synaptic functions. 68”
From Senescence, brain inflammation, and oligomeric tau drive cognitive decline in Alzheimer's disease: Evidence from clinical and preclinical studies (2024) · cites this paper as [68]
In the citing paper
“A recent study shows that NLR family pyrin domain-containing protein 3 (NLRP3) inflammasome activation induces tau hyperphosphorylation and aggregation through modulating tau kinases and phosphatases [159].”
From Tau and neuroinflammation in Alzheimer’s disease: interplay mechanisms and clinical translation (2023) · cites this paper as [159]
In the citing paper
“In the CNS, inflammasome activation has been mainly linked to neuroinflammatory conditions. As example, it has an essential role in the progression of several neurological disorders like MS, AD, PPD, and NPS (132, 193–197).”
From The gut-brain axis: how microbiota and host inflammasome influence brain physiology and pathology (2020) · cites this paper as [197]
In the citing paper
“In general, patients affected by tauopathies showed elevated levels of cleaved caspase-1 and ASC and mature IL-1β in the cortex (197).”
From The gut-brain axis: how microbiota and host inflammasome influence brain physiology and pathology (2020) · cites this paper as [197]
In the citing paper
“Injecting brain homogenates from APP/PS1 or wild-type mice into the hippocampus of Tau22 mice, induced tau hyperphosphorylation in the hippocampus of Tau22 wild-type but not Tau22/Pycard−/− or Tau22/Nlrp3−/− deficient mice”
From The gut-brain axis: how microbiota and host inflammasome influence brain physiology and pathology (2020) · cites this paper as [197]
In the citing paper
“suggesting that NLRP3 activation is upstream the Aβ-tau cascade and tau pathology (197).”
From The gut-brain axis: how microbiota and host inflammasome influence brain physiology and pathology (2020) · cites this paper as [197]
In the citing paper
“Consistent with this, Tau22 mice lacking ASC or NLRP3 expression had lower levels of aggregated and hyperphosphorylated tau in the hippocampus, and their typical spatial memory deficits were rescued (197).”
From The gut-brain axis: how microbiota and host inflammasome influence brain physiology and pathology (2020) · cites this paper as [197]
In the citing paper
“Also, Tau22 mice, another model of AD and other tauopathies, had increased levels of cleaved caspase-1 and ASC in their brain at the age of 11 months compared to their 3-month-old counterparts.”
From The gut-brain axis: how microbiota and host inflammasome influence brain physiology and pathology (2020) · cites this paper as [197]
In the citing paper
“Further, activated microglia promote tau phosphorylation and aggregation by activation of the NLRP3 (nucleotide binding oligomerisation domain (NOD)-, leucine-rich repeat (LRR)- and pyrin domain-containing protein 3) inflammasome in response to amyloid-β [22,23].”
From ROS Generation in Microglia: Understanding Oxidative Stress and Inflammation in Neurodegenerative Disease (2020) · cites this paper as [23]
In the citing paper
“Further, there is evidence tauopathy is driven by NLRP3 inflammasome activation in microglia in response to amyloid-β [23].”
From ROS Generation in Microglia: Understanding Oxidative Stress and Inflammation in Neurodegenerative Disease (2020) · cites this paper as [23]
In the citing paper
“ROS from NOX4 also contribute to activation of the NLRP3 inflammasome, a driver of both amyloid-β [156] and tau [23] pathology.”
From ROS Generation in Microglia: Understanding Oxidative Stress and Inflammation in Neurodegenerative Disease (2020) · cites this paper as [23]
In the citing paper
“Growing evidence indicates that Aβ accumulation stimulates tau phosphorylation and fibrillary tangle formation, leading to the process of neurodegeneration.112–114”
From Amyloid β-based therapy for Alzheimer’s disease: Challenges, successes and future (2023) · cites this paper as [112]
In the citing paper
“In particular, microglial NLRP3 has been shown to be a major driver of amyloid beta and tau toxicity in AD, suggesting its activation has important implications for disease progression (Halle et al, 2008; Venegas et al, 2017; Ising et al, 2019).”
From Mechanisms of DNA damage-mediated neurotoxicity in neurodegenerative disease (2022) · cites this paper as Ising et al, 2019
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Szklarczyk, D., Morris, J. H., Cook, H., Kuhn, M., Wyder, S., Simonovic, M., Santos, A., Doncheva, N. T., Roth, A., Bork, P., et al. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkw937 · Cited by 6,980
NLRP3 is activated in Alzheimer’s disease and contributes to pathology in APP/PS1 mice
Heneka, M. T., Kummer, M. P., Stutz, A., Delekate, A., Schwartz, S., Vieira-Saecker, A., Griep, A., Axt, D., Remus, A., Tzeng, T.-C., et al. (2013) · Nature · doi:10.1038/nature11729 · Cited by 2,898
Self-citationThe NALP3 inflammasome is involved in the innate immune response to amyloid-β
Halle, A., Hornung, V., Petzold, G. C., Stewart, C. R., Monks, B. G., Reinheckel, T., Fitzgerald, K. A., Latz, E., Moore, K. J., & Golenbock, D. T. (2008) · Nature Immunology · doi:10.1038/ni.1636 · Cited by 2,441
Self-citationDepletion of microglia and inhibition of exosome synthesis halt tau propagation
Asai, H., Ikezu, S., Tsunoda, S., Medalla, M., Luebke, J., Haydar, T., Wolozin, B., Butovsky, O., Kügler, S., & Ikezu, T. (2015) · Nature Neuroscience · doi:10.1038/nn.4132 · Cited by 1,591
Formation of Neurofibrillary Tangles in P301L Tau Transgenic Mice Induced by Aβ42 Fibrils
Götz, J., Chen, F., van Dorpe, J., & Nitsch, R. M. (2001) · Science · doi:10.1126/science.1062097 · Cited by 1,526
Bacterial RNA and small antiviral compounds activate caspase-1 through cryopyrin/Nalp3
Kanneganti, T., Özören, N., Body–Malapel, M., Amer, A. O., Park, J., Franchi, L., Whitfield, J. R., Barchet, W., Colonna, M., Vandenabeele, P., et al. (2006) · Nature · doi:10.1038/nature04517 · Cited by 1,149
Tau pathology in Alzheimer disease and other tauopathies
Iqbal, K., del C. Alonso, A., Chen, S., Chohan, M. O., El-Akkad, E., Gong, C.-X., Khatoon, S., Li, B., Liu, F., Rahman, A., et al. (2005) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2004.09.008 · Cited by 1,037
Microglia-derived ASC specks cross-seed amyloid-β in Alzheimer’s disease
Venegas, C., Kumar, S., Franklin, B. S., Dierkes, T., Brinkschulte, R., Tejera, D., Vieira-Saecker, A., Schwartz, S., Santarelli, F., Kummer, M. P., et al. (2017) · Nature · doi:10.1038/nature25158 · Cited by 983
Self-citationInflammasome signalling in brain function and neurodegenerative disease
Heneka, M. T., McManus, R. M., & Latz, E. (2018) · Nature Reviews Neuroscience · doi:10.1038/s41583-018-0055-7 · Cited by 836
Self-citationCanonical Nlrp3 Inflammasome Links Systemic Low-Grade Inflammation to Functional Decline in Aging
Youm, Y.-H., Grant, R. W., McCabe, L. R., Albarado, D. C., Nguyen, K. Y., Ravussin, A., Pistell, P., Newman, S., Carter, R., Laque, A., et al. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.09.010 · Cited by 674
Cited by
Sorted by citations
Items 101–200 of 1,003
The endotoxin hypothesis of Alzheimer’s disease
Brown, G. C., & Heneka, M. T. (2024) · Molecular Neurodegeneration · doi:10.1186/s13024-024-00722-y · Cited by 148
Self-citationZhao, Y., Zeng, C., Li, X., Yang, T., Kuang, X., & Du, J. (2020) · Aging Cell · doi:10.1111/acel.13239 · Cited by 135
An exhausted-like microglial population accumulates in aged and APOE4 genotype Alzheimer’s brains
Millet, A., Ledo, J. H., & Tavazoie, S. F. (2024) · Immunity · doi:10.1016/j.immuni.2023.12.001 · Cited by 132
Margeta, M. A., Yin, Z., Madore, C., Pitts, K. M., Letcher, S. M., Tang, J., Jiang, S., Gauthier, C. D., Silveira, S. R., Schroeder, C. M., et al. (2022) · Immunity · doi:10.1016/j.immuni.2022.07.014 · Cited by 130
Mechanisms of DNA damage-mediated neurotoxicity in neurodegenerative disease
Welch, G., & Tsai, L. (2022) · The EMBO Reports · doi:10.15252/embr.202154217 · Cited by 129
Alzheimer’s Retinopathy: Seeing Disease in the Eyes
Mirzaei, N., Shi, H., Oviatt, M., Doustar, J., Rentsendorj, A., Fuchs, D.-T. S., Sheyn, J., Black, K. L., Koronyo, Y., & Koronyo‐Hamaoui, M. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00921 · Cited by 136
Transgenic Mouse Models of Alzheimer’s Disease: An Integrative Analysis
Sanchez-Varo, R. M., Mejias‐Ortega, M., Fernandez-Valenzuela, J. J., Nuñez‐Diaz, C., Cáceres-Palomo, L., Vegas‐Gomez, L., Sánchez‐Mejías, E., Trujillo‐Estrada, L., García‐León, J. A., Moreno‐González, I., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23105404 · Cited by 136
NLRP3 inflammasome as a novel therapeutic target for Alzheimer’s disease
Zhang, Y., Dong, Z., & Song, W. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0145-7 · Cited by 128
Trem2 deletion enhances tau dispersion and pathology through microglia exosomes
Zhu, B., Liu, Y., Hwang, S., Archuleta, K., Huang, H., Campos, A., Murad, R., Piña-Crespo, J., Xu, H., & Huang, T. Y. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00562-8 · Cited by 127
Activation of NLRP3 Inflammasome and Onset of Alzheimer’s Disease
Bai, H., & Zhang, Q. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.701282 · Cited by 132
TREM2: Potential therapeutic targeting of microglia for Alzheimer's disease
Li, Y., Xu, H., Wang, H., Yang, K., Luan, J., & Wang, S. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115218 · Cited by 133
Microbiome or Infections: Amyloid-Containing Biofilms as a Trigger for Complex Human Diseases
Miller, A. L., Bessho, S., Grando, K. C. M., & Tükel, Ç. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.638867 · Cited by 136
Mechanisms of NLRP3 Inflammasome Activation: Its Role in the Treatment of Alzheimer’s Disease
Zhang, Y., Zhao, Y., Zhang, J., & Yang, G. (2020) · Neurochemical Research · doi:10.1007/s11064-020-03121-z · Cited by 127
Microglia in Alzheimer’s Disease in the Context of Tau Pathology
Perea, J. R., Bolós, M., & Ávila, J. (2020) · Biomolecules · doi:10.3390/biom10101439 · Cited by 134
Reactive microglia enhance the transmission of exosomal α-synuclein via toll-like receptor 2
Xia, Y., Zhang, G., Kou, L., Yin, S., Han, C., Hu, J., Wan, F., Sun, Y., Wu, J., Li, Y., et al. (2021) · Brain · doi:10.1093/brain/awab122 · Cited by 123
NLRP3 inflammasome signalling in Alzheimer's disease
McManus, R. M., & Latz, E. (2024) · Neuropharmacology · doi:10.1016/j.neuropharm.2024.109941 · Cited by 136
Self-citationKobro-Flatmoen, A., Lagartos-Donate, M. J., Aman, Y., Edison, P., Witter, M. P., & Fang, E. F. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101307 · Cited by 119
The role of innate immunity in Alzheimer's disease
Ennerfelt, H. E., & Lukens, J. R. (2020) · Immunological Reviews · doi:10.1111/imr.12896 · Cited by 124
Satoh, T., Trudler, D., Oh, C.-K., & Lipton, S. A. (2022) · Antioxidants · doi:10.3390/antiox11010124 · Cited by 126
Microglial Calhm2 regulates neuroinflammation and contributes to Alzheimer’s disease pathology
Cheng, J., Dong, Y., Ma, J., Pan, R., Liao, Y., Kong, X., Li, X., Li, S., Chen, P.-F., Wang, L., et al. (2021) · Science Advances · doi:10.1126/sciadv.abe3600 · Cited by 121
Gaikwad, S., Senapati, S., Haque, M. A., & Kayed, R. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.13490 · Cited by 117
Self-citationContribution of astrocytes to neuropathology of neurodegenerative diseases
Acıoğlu, Ç., Li, L., & Elkabes, S. (2021) · Brain Research · doi:10.1016/j.brainres.2021.147291 · Cited by 119
Neuropathogenesis-on-chips for neurodegenerative diseases
Amartumur, S., Nguyen, H. M., Huynh, T., Kim, T. S., Woo, R., Oh, E., Kim, K. K., Lee, L. P., & Heo, C. (2024) · Nature Communications · doi:10.1038/s41467-024-46554-8 · Cited by 131
Milligan Armstrong, A., Porter, T., Quek, H., White, A., Haynes, J., Jackaman, C., Villemagne, V., Munyard, K., Laws, S. M., Verdile, G., et al. (2021) · Biological Reviews · doi:10.1111/brv.12750 · Cited by 116
Spermidine reduces neuroinflammation and soluble amyloid beta in an Alzheimer’s disease mouse model
Freitag, K., Sterczyk, N., Wendlinger, S., Obermayer, B., Schulz, J., Farztdinov, V. M., Mülleder, M., Ralser, M., Houtman, J., Fleck, L., et al. (2022) · Journal of Neuroinflammation · doi:10.1186/s12974-022-02534-7 · Cited by 125
TREM2-independent microgliosis promotes tau-mediated neurodegeneration in the presence of ApoE4.
Gratuze, M., Schlachetzki, J. C. M., D’Oliveira Albanus, R., Jain, N., Novotny, B., Brase, L., Rodriguez, L., Mansel, C., Kipnis, M., O’Brien, S., et al. (2023) · Neuron · doi:10.1016/j.neuron.2022.10.022 · Cited by 115
Noncanonical function of an autophagy protein prevents spontaneous Alzheimer’s disease
Heckmann, B. L., Teubner, B. J. W., Boada-Romero, E., Tummers, B., Guy, C., Fitzgerald, P., Mayer, U., Carding, S., Zakharenko, S. S., Wileman, T., et al. (2020) · Science Advances · doi:10.1126/sciadv.abb9036 · Cited by 114
Penke, B., Szűcs, M., & Bogár, F. (2020) · Molecules · doi:10.3390/molecules25071659 · Cited by 119
The role of the immune system in Alzheimer’s disease
Wu, K., Zhang, Y.-R., Huang, Y., Dong, Q., Tan, L., & Yu, J. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101409 · Cited by 119
Function and inhibition of P38 MAP kinase signaling: Targeting multiple inflammation diseases
Wang, J., Liu, Y., Guo, Y., Liu, C., Yang, Y., Fan, X., Yang, H., Liu, Y., & Ma, T. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115973 · Cited by 120
A genetic link between risk for Alzheimer's disease and severe COVID-19 outcomes via the OAS1 gene
Magusali, N., Graham, A. C., Piers, T. M., Panichnantakul, P., Yaman, U., Shoai, M., Reynolds, R. H., Botia, J. A., Brookes, K. J., Guetta-Baranes, T., et al. (2021) · Brain · doi:10.1093/brain/awab337 · Cited by 111
SGK1 inhibition in glia ameliorates pathologies and symptoms in Parkinson disease animal models
Kwon, O., Song, J., Yang, Y., Kim, S., Kim, J. Y., Seok, M., Hwang, I., Yu, J., Karmacharya, J., Maeng, H., et al. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202013076 · Cited by 110
Chiral nanoparticle-remodeled gut microbiota alleviates neurodegeneration via the gut–brain axis
Guo, X. L., Li, C., Zhang, J., Sun, M., Xu, J., Xu, C., Kuang, H., & Xu, L. (2023) · Nature Aging · doi:10.1038/s43587-023-00516-9 · Cited by 119
Babuta, M., Morel, C., Ribeiro, M. D. C., Calenda, C. D., Ortega‐Ribera, M., Nagesh, P. T., Copeland, C., Zhuang, Y., Wang, Y., Cho, Y., et al. (2024) · Gut · doi:10.1136/gutjnl-2023-331447 · Cited by 121
Microglia Polarization in Alzheimer’s Disease: Mechanisms and a Potential Therapeutic Target
Wang, Q., Yao, H., Liu, W., Ya, B., Cheng, H., Xing, Z., & Wu, Y. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.772717 · Cited by 111
TRPV1 channel mediates NLRP3 inflammasome-dependent neuroinflammation in microglia
Zhang, Y., Hou, B., Liang, P., Lu, X., Wu, Y., Zhang, X., Fan, Y., Liu, Y., Chen, T.-X., Liu, W., et al. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-04450-9 · Cited by 107
Chen, J., Mao, K., Yu, H., Wen, Y., She, H., Yang, L., Zhang, H., Li, M., Wu, X., Ren, Y., et al. (2021) · Journal of Neuroinflammation · doi:10.1186/s12974-021-02349-y · Cited by 111
Kodali, M., Madhu, L. N., Reger, R. L., Milutinovic, B. S., Upadhya, R., Gonzalez, J. J., Attaluri, S., Shuai, B., Gitaí, D. L. G., Rao, S., et al. (2022) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2022.11.014 · Cited by 111
Nanoparticles: A Hope for the Treatment of Inflammation in CNS
Zhu, F., Hu, Y.-J., Yu, L., Zhou, X., Wu, J., Tang, Y., Qin, D., Fan, Q., & Wu, A. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.683935 · Cited by 110
Li, T., Lu, L., Pember, E., Li, X., Zhang, B., & Zhu, Z. (2022) · Cells · doi:10.3390/cells11121925 · Cited by 109
Alzheimer’s Disease: Etiology, Neuropathology and Pathogenesis
Sheppard, O., & Coleman, M. P. (2020) · Exon Publications eBooks · doi:10.36255/exonpublications.alzheimersdisease.2020.ch1 · Cited by 127
A Potential Link Between Visceral Obesity and Risk of Alzheimer’s Disease
Al-Kuraishy, H. M., Al-Gareeb, A. I., Alsayegh, A. A., Hakami, Z. H., Khamjan, N. A., Saad, H. M., Batiha, G. E., & WAARD, M. M. D. (2022) · Neurochemical Research · doi:10.1007/s11064-022-03817-4 · Cited by 106
The lipid basis of cell death and autophagy
Lin, Z., Long, F., Kang, R., Klionsky, D. J., Yang, M., & Tang, D. (2023) · Autophagy · doi:10.1080/15548627.2023.2259732 · Cited by 107
Recent Progress and Prospects of Small Molecules for NLRP3 Inflammasome Inhibition
Li, N., Zhang, R., Tang, M., Zhao, M., Jiang, X., Cai, X., Ye, N., Su, K., Peng, J., Zhang, X., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01370 · Cited by 104
Alterations in the Gut-Microbial-Inflammasome-Brain Axis in a Mouse Model of Alzheimer’s Disease
Shukla, P. K., Delotterie, D. F., Xiao, J., Pierre, J. F., Rao, R., McDonald, M. P., & Khan, M. M. (2021) · Cells · doi:10.3390/cells10040779 · Cited by 105
Inflammasomes in neurological disorders — mechanisms and therapeutic potential
Ravichandran, K. A., & Heneka, M. T. (2024) · Nature Reviews Neurology · doi:10.1038/s41582-023-00915-x · Cited by 112
Self-citationXu, F., Mu, J., Teng, Y., Zhang, X., Sundaram, K., Sriwastva, M. K., Kumar, A., Lei, C., Zhang, L., Liu, Q. M., et al. (2021) · Small · doi:10.1002/smll.202105385 · Cited by 106
Increasing complexity of NLRP3 inflammasome regulation
Moretti, J., & Blander, J. M. (2020) · Journal of Leukocyte Biology · doi:10.1002/jlb.3mr0520-104rr · Cited by 107
Verma, A., Shteinfer‐Kuzmine, A., Kamenetsky, N., Pittala, S., Paul, A., Crystal, E. N., Ouro, A., Caspi, V. C., Pandey, S. K., Monsonego, A., et al. (2022) · Translational Neurodegeneration · doi:10.1186/s40035-022-00329-7 · Cited by 109
Mitochondrial dysfunction in chronic neuroinflammatory diseases (Review)
Qin, P., Sun, Y., & Li, L. (2024) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2024.5371 · Cited by 106
Xu, L., Gao, H., Zhan, W., Deng, Y., Liu, X., Jiang, Q., Sun, X., Xu, J., & Liang, G. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.3c10255 · Cited by 98
Calderón‐Garcidueñas, L., González-Maciel, A., Reynoso-Robles, R., Hammond, J., Kulesza, R. J., Lachmann, I., Torres‐Jardón, R., Mukherjee, P. S., & Maher, B. A. (2020) · Environmental Research · doi:10.1016/j.envres.2020.110139 · Cited by 98
Long, H., Zhou, Z.-W., Cheng, Y., Luo, H., Li, F., Xu, S., & Gao, L. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.888989 · Cited by 100
Gabandé‐Rodríguez, E., Heras, M. M. G. D. L., & Mittelbrunn, M. (2019) · Cells · doi:10.3390/cells9010082 · Cited by 101
NLRP3 Ubiquitination—A New Approach to Target NLRP3 Inflammasome Activation
Akther, M., Haque, M. E., Park, J., Kang, T., & Lee, K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168780 · Cited by 95
Terzioglu, G., & Young-Pearse, T. L. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00674-9 · Cited by 91
Transcriptional Regulation of Inflammasomes
Cornut, M., Bourdonnay, E., & Henry, T. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218087 · Cited by 98
Xin, Y., Tian, M., Deng, S., Li, J., Yang, M., Gao, J., Pei, X., Wang, Y., Tan, J., Zhao, F., et al. (2022) · Molecular Neurobiology · doi:10.1007/s12035-022-03148-z · Cited by 102
Rexach, J. E., Polioudakis, D., Yin, A., Swarup, V., Chang, T. S., Nguyen, T., Sarkar, A., Chen, L., Huang, J., Lin, L.-C., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108398 · Cited by 94
Bibliometric Analysis of the Inflammasome and Pyroptosis in Brain
Chen, Y., Li, Y., Guo, L., Hong, J. Y., Zhao, W., Hu, X., Chang, C., Liu, W., & Xiong, K. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.626502 · Cited by 94
Fueling neurodegeneration: metabolic insights into microglia functions
Sadeghdoust, M., Das, A., & Kaushik, D. K. (2024) · Journal of Neuroinflammation · doi:10.1186/s12974-024-03296-0 · Cited by 107
Gao, C., Chu, X., Gong, W., Zheng, J., Xie, X., Yang, M., Yang, M., Li, Z., Gao, C., & Yang, Y. (2020) · Journal of Nanobiotechnology · doi:10.1186/s12951-020-00626-1 · Cited by 94
RetractedHenriques, J. F., Serra, D., Dinis, T. C. P., & Almeida, L. M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228653 · Cited by 95
Harrison, D., Billinton, A., Bock, M. G., Doedens, J. R., Gabel, C. A., Holloway, M. K., Porter, R. A., Reader, V., Scanlon, J., Schooley, K., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01398 · Cited by 93
Jiang, S., Maphis, N. M., Binder, J., Chisholm, D., Weston, L., Duran, W., Peterson, C., Zimmerman, A., Mandell, M. A., Jett, S. D., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109720 · Cited by 92
Self-citationJung, E. S., Suh, K., Han, J., Kim, H., Kang, H., Choi, W., & Mook‐Jung, I. (2022) · Aging Cell · doi:10.1111/acel.13623 · Cited by 97
Dubey, S. R., Turnbull, C., Pandey, A., Zhao, A., Kurera, M., Al-Zidan, R. N., Shen, C. X., Gautam, M., Mahajan, S., Jadhav, P. S., et al. (2025) · Cellular and Molecular Immunology · doi:10.1038/s41423-025-01354-y · Cited by 101
Tao, X., Wan, X., Wu, D., Song, E., & Song, Y. (2021) · Journal of Hazardous Materials · doi:10.1016/j.jhazmat.2021.125134 · Cited by 89
The NLRP3 Inflammasome as a Critical Actor in the Inflammaging Process
Sebastian-Valverde, M., & Pasinetti, G. M. (2020) · Cells · doi:10.3390/cells9061552 · Cited by 90
Early life adversity as a risk factor for cognitive impairment and Alzheimer’s disease
Huang, Z., Jordan, J. D., & Zhang, Q. (2023) · Translational Neurodegeneration · doi:10.1186/s40035-023-00355-z · Cited by 98
Kynurenine Pathway Metabolites as Biomarkers in Alzheimer’s Disease
Liang, Y., Xie, S., He, Y., Xu, M., Qiao, X., Zhu, Y. H., & Wu, W. (2022) · Disease Markers · doi:10.1155/2022/9484217 · Cited by 92
de Dios, C., Abadin, X., Roca-Agujetas, V., Jimenez-Martinez, M., Morales, A., Trullas, R., Mari, M., & Colell, A. (2023) · Translational Neurodegeneration · doi:10.1186/s40035-023-00343-3 · Cited by 85
Zheng, Q., Li, G., Wang, S., Zhou, Y., Liu, K., Gao, Y., Zhou, Y., Zheng, L., Zhu, L., Deng, Q., et al. (2021) · Science Advances · doi:10.1126/sciadv.abe1340 · Cited by 85
Yang, G., Xu, X., Gao, W., Wang, X., Zhao, Y., & Xu, Y. (2025) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2025.1700692 · Cited by 85
Precision Nutrition for Alzheimer’s Prevention in ApoE4 Carriers
Norwitz, N. G., Saif, N., Ariza, I. E., & Isaacson, R. (2021) · Nutrients · doi:10.3390/nu13041362 · Cited by 92
Role of Extracellular Vesicles in Cell Death and Inflammation
Sanwlani, R., & Gangoda, L. (2021) · Cells · doi:10.3390/cells10102663 · Cited by 90
Zhang, X., Tang, L., Yang, J., Meng, L., Chen, J., Zhou, L., Wang, J., Xiong, M., & Zhang, Z. (2023) · Nature Communications · doi:10.1038/s41467-023-42505-x · Cited by 91
Inflammasome assembly in neurodegenerative diseases
Singh, J., Habean, M. L., & Panicker, N. (2023) · Trends in Neurosciences · doi:10.1016/j.tins.2023.07.009 · Cited by 83
Kuwar, R., Rolfe, A., Di, L., Blevins, H., Xu, Y., Sun, X., Bloom, G. S., Zhang, S., & Sun, D. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210400 · Cited by 82
Self-citationTau at the interface between neurodegeneration and neuroinflammation
Didonna, A. (2020) · Genes & Immunity · doi:10.1038/s41435-020-00113-5 · Cited by 82
Regulation of the NLRP3 Inflammasome by Post-Translational Modifications and Small Molecules
Seok, J. K., Kang, H. C., Cho, Y., Lee, H. S., & Lee, J. Y. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.618231 · Cited by 88
Litwiniuk, A., Bik, W., Kalisz, M., & Baranowska-Bik, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115603 · Cited by 82
Greve, H. J., Dunbar, A. L., Lombo, C. G., Ahmed, C., Thang, M., Messenger, E. J., Mumaw, C. L., Johnson, J. A., Kodavanti, U. P., Oblak, A. L., et al. (2023) · Brain · doi:10.1093/brain/awac113 · Cited by 82
Oxidative stress–mediated neuroinflammation in Alzheimer’s disease
Firdous, S. M., Khan, S. A., & Maity, A. (2024) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-024-03188-3 · Cited by 90
APOE ε4 associates with microglial activation independently of Aβ plaques and tau tangles
Ferrari-Souza, J. P., Lussier, F. Z., Leffa, D. T., Therriault, J., Tissot, C., Bellaver, B., Ferreira, P. C. L., Malpetti, M., Wang, Y.-T., Povala, G., et al. (2023) · Science Advances · doi:10.1126/sciadv.ade1474 · Cited by 81
Hochheiser, I. V., Behrmann, H., Hagelueken, G., Rodríguez-Alcázar, J. F., Kopp, A., Latz, E., Behrmann, E., & Geyer, M. (2022) · Science Advances · doi:10.1126/sciadv.abn7583 · Cited by 82
Self-citationA one-two punch targeting reactive oxygen species and fibril for rescuing Alzheimer’s disease
Wang, J., Shangguan, P., Chen, X., Zhong, Y., Lin, M., He, M., Liu, Y., Zhou, Y. L., Pang, X., Han, L., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-44737-x · Cited by 84
Chronic effects of inflammation on tauopathies
Langworth-Green, C., Patel, S., Jaunmuktane, Z., Jabbari, E., Morris, H. R., Thom, M., Lees, A. J., Hardy, J., Zandi, M. S., & Duff, K. (2023) · The Lancet Neurology · doi:10.1016/s1474-4422(23)00038-8 · Cited by 85
The roles of microglia and astrocytes in neuroinflammation of Alzheimer’s disease
Han, J., Zhang, Z., Zhang, P., Yu, Q., Cheng, Q., Lu, Z., & Zong, S. (2025) · Frontiers in Neuroscience · doi:10.3389/fnins.2025.1575453 · Cited by 97
INPP5D regulates inflammasome activation in human microglia
Chou, V., Pearse, R. V., Aylward, A. J., Ashour, N., Taga, M., Terzioglu, G., Fujita, M., Fancher, S. B., Sigalov, A., Benoit, C. R., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-42819-w · Cited by 79
Identification of Conserved Proteomic Networks in Neurodegenerative Dementia
Swarup, V., Chang, T. S., Duong, D. M., Dammer, E. B., Dai, J., Lah, J. J., Johnson, E. C. B., Seyfried, N. T., Levey, A. I., & Geschwind, D. H. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107807 · Cited by 78
Identification of conserved proteomic networks in neurodegenerative dementia
Swarup, V., Chang, T. S., Duong, D. M., Dammer, E. B., Lah, J. J., Johnson, E. E. C. B., Seyfried, N. T., Levey, A. I., & Geschwind, D. H. (2019) · doi:10.1101/825802 · Cited by 78
LncRNA-Meg3 promotes Nlrp3-mediated microglial inflammation by targeting miR-7a-5p
Meng, J., Ding, T., Chen, Y., Long, T., Xu, Q., Lian, W.-Q., & Liu, W. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.107141 · Cited by 78
Neuronal and glial CSF biomarkers in multiple sclerosis: a systematic review and meta-analysis
Momtazmanesh, S., Shobeiri, P., Saghazadeh, A., Teunissen, C. E., Burman, J., Szalárdy, L., Klivènyi, P., Bartoš, A., Fernandes, A. M. A., & Rezaei, N. (2021) · Reviews in the Neurosciences · doi:10.1515/revneuro-2020-0145 · Cited by 84
SFRP1 modulates astrocyte-to-microglia crosstalk in acute and chronic neuroinflammation
Rueda‐Carrasco, J., Martín‐Bermejo, M. J., Pereyra, G., Mateo, M. I., Borroto, A., Brosseron, F., Kummer, M. P., Schwartz, S., López‐Atalaya, J. P., Alarcón, B., et al. (2021) · EMBO Reports · doi:10.15252/embr.202051696 · Cited by 79
Self-citationPeripheral and central neuroimmune mechanisms in Alzheimer’s disease pathogenesis
Zhang, S., Gao, Y., Zhao, Y., Huang, T. Y., Zheng, Q., & Wang, X. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00812-5 · Cited by 78
Self-citationHeneka, M. T., Gauthier, S. G., Chandekar, S. A., Hahn-Pedersen, J. H., Bentsen, M. A., & Zetterberg, H. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-02939-9 · Cited by 97
Self-citationRabin, J. S., Nichols, E., Joie, R. L., Casaletto, K. B., Palta, P., Dams-O’Connor, K., Kumar, R. G., George, K. M., Satizábal, C. L., Schneider, J. A., et al. (2022) · Brain · doi:10.1093/brain/awac178 · Cited by 80
DNA damage contributes to neurotoxic inflammation in Aicardi-Goutières syndrome astrocytes
Giordano, A. M. S., Luciani, M., Gatto, F., Abou Alezz, M., Beghè, C., Della Volpe, L., Migliara, A., Valsoni, S., Genua, M., Dzieciatkowska, M., et al. (2022) · Journal of Experimental Medicine · doi:10.1084/jem.20211121 · Cited by 76
Programmed Death of Microglia in Alzheimer's Disease: Autophagy, Ferroptosis, and Pyroptosis
Qiu, Z., Zhang, H., Xia, M., Gu, J., Guo, K., Wang, H., & Miao, C. (2023) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2023.3 · Cited by 77
Metadata
- Authors
- Ising, C., Venegas, C., Zhang, S., Scheiblich, H., Schmidt, S. V., Vieira-Saecker, A., Schwartz, S., Albasset, S., McManus, R. M., Tejera, D., Griep, A., Santarelli, F., Brosseron, F., Opitz, S., Stunden, J., Merten, M., Kayed, R., Golenbock, D. T., Blum, D., Latz, E., Buée, L., & Heneka, M. T.
- Affiliations
- University Hospital Bonn (DE)
- German Center for Neurodegenerative Diseases (DE)
- The University of Texas Medical Branch at Galveston (US)
- University of Massachusetts Chan Medical School (US)
- Inserm (FR)
- Corresponding author
- Heneka, Michael T.
- ORCID
- Venue
- Nature
- Published
- 2019-11-20
- Volume
- 575
- Issue
- 7784
- Pages
- 669-673
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC7324015
- OpenAlex
- W2990312754
- Semantic Scholar
- 6a9d745a33a2d013c621f57586d9d719671530a7
- Cited by
- 1,487
- References
- 28
- Citations by year
- 2026: 189 · 2025: 226 · 2024: 255 · 2023: 226 · 2022: 248 · 2021: 193 · 2020: 143 · 2019: 3
- FWCI
- 101.29
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Open Repository and Bibliography (University of Luxembourg) (submittedVersion, other-oa)
- HAL (submittedVersion, other-oa)
- RePEc: Research Papers in Economics (submittedVersion)
- Institutional Repository of the University of Granada (University of Granada) (submittedVersion, cc-by-nc-nd)
- DZNE Pub (submittedVersion)
- Funders
- Deutsche Forschungsgemeinschaft (R01 AG059752-02)
- Agence Nationale de la Recherche (ANR-11-LABX-0009)
- Deutsches Zentrum für Neurodegenerative Erkrankungen
- National Institutes of Health
- National Institute on Aging (R01AG059752, R01AG054025)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Inflammasome and immune disorders
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- NLRP3 inflammasome, tau hyperphosphorylation, tau aggregation, neurofibrillary tangles, Alzheimer's disease, amyloid-beta, microglia, amyloid hypothesis, frontotemporal dementia, neuroinflammation, caspase-1, IL-1β
- MeSH terms
- NLR Family, Pyrin Domain-Containing 3 Protein, Animals, Gene Expression Regulation, Humans, Mice, Inbred C57BL, Phosphorylation, tau Proteins, Microglia, Cyclin-Dependent Kinase 5, Mice, Inflammasomes, Protein Aggregation, Pathological
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
